Sign inCreate account

Report workspace tools

NCT02299817UNKNOWNanonymous

Denosumab for Treating Periprosthetic Osteolysis After Uncemented Total Hip Arthroplasty A Randomized, Double-blind, Placebo-controlled Trial Using Volumetric Computed Tomography

Sponsor

Source record

Olof Skoldenberg

Phase

Source record

PHASE2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Osteolysis

Indication / condition

AI-normalized

Osteolysis

Intervention

Source record

Denosumab, Placebo

Source & freshness

Source record

NCT ID

NCT02299817

Original source

ClinicalTrials.gov

Source last updated

Feb 07, 2019

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02299817

Title

Denosumab for Treating Periprosthetic Osteolysis After Uncemented Total Hip Arthroplasty A Randomized, Double-blind, Placebo-controlled Trial Using Volumetric Computed Tomography

Sponsor

Olof Skoldenberg

Status

UNKNOWN

Phase

PHASE2

Condition raw

Osteolysis

Condition normalized

Osteolysis

Modality raw

Osteolysis

Modality normalized

monoclonal antibody

Target raw

Osteolysis

Target normalized

Osteolysis

Interventions

Denosumab, Placebo

Public preview

Source record

This clinical trial investigates the efficacy of denosumab in reducing wear-induced osteolysis around uncemented acetabular implants in total hip arthroplasty. The study aims to provide insights into the potential of denosumab as a treatment option for patients experiencing osteolysis post-surgery.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Denosumab for Treating Periprosthetic Osteolysis After Uncemented Total Hip Arthroplasty A Randomized, Double-blind, Placebo-controlled Trial Using Volumetric Computed Tomography

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02299817

Status

UNKNOWN

Phase

PHASE2

Sponsor

Olof Skoldenberg

Executive brief

Investment-Ready Snapshot

This clinical trial investigates the efficacy of denosumab in reducing wear-induced osteolysis around uncemented acetabular implants in total hip arthroplasty. The study aims to provide insights into the potential of denosumab as a treatment option for patients experiencing osteolysis post-surgery.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 07, 2019
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02299817

Indication

Osteolysis

Modality

monoclonal antibody

Target

Osteolysis

Intervention

Denosumab, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.